MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.numecd.2021.01.019

Медицинская библиотека · Nutrition, metabolism, and cardiovascular diseases : NMCD · 2021

Bone fragility in patients with diabetes mellitus: A consensus statement from the working group of the Italian Diabetes Society (SID), Italian Society of Endocrinology (SIE), Italian Society of Gerontology and Geriatrics (SIGG), Italian Society of Orthopaedics and Traumatology (SIOT).

Napoli Nicola, Incalzi Raffaele A, De Gennaro Giovanni, Marcocci Claudio, Marfella Raffaele, Papalia Rocco, Purrello Francesco, Ruggiero Carmelinda, Tarantino Umberto, Tramontana Flavia, Conte Caterina

СтатьяПоддержка исследования: вне правительства СШАОбзорConsensus StatementПеревод в очереди

Аннотация

Bone fragility is one of the possible complications of diabetes, either type 1 (T1D) or type 2 (T2D). Bone fragility can affect patients of different age and with different disease severity depending on type of diabetes, disease duration and the presence of other complications. Fracture risk assessment should be started at different stages in the natural history of the disease depending on the type of diabetes and other risk factors. The risk of fracture in T1D is higher than in T2D, imposing a much earlier screening and therapeutic intervention that should also take into account a patient's life expectancy, diabetes complications etc. The therapeutic armamentarium for T2D has been enriched with drugs that may influence bone metabolism, and clinicians should be aware of these effects. Considering the complexity of diabetes and osteoporosis and the range of variables that influence treatment choices in a given individual, the Working Group on bone fragility in patients with diabetes mellitus has identified and issued recommendations based on the variables that should guide screening of bone fragility and management of diabetes and bone fragility: (A)ge, (B)MD, (C)omplications, (D)uration of disease, & (F)ractures (ABCD&F). Consideration of these parameters may help clinicians identify the best time for screening, the appropriate glycaemic target and anti-osteoporosis drug for patients with diabetes at risk of or with bone fragility.

Для цитирования: Napoli Nicola, Incalzi Raffaele A, De Gennaro Giovanni, Marcocci Claudio, Marfella Raffaele, Papalia Rocco, Purrello Francesco, Ruggiero Carmelinda, Tarantino Umberto, Tramontana Flavia, Conte Caterina. Bone fragility in patients with diabetes mellitus: A consensus statement from the working group of the Italian Diabetes Society (SID), Italian Society of Endocrinology (SIE), Italian Society of Gerontology and Geriatrics (SIGG), Italian Society of Orthopaedics and Traumatology (SIOT).. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2021. DOI: 10.1016/j.numecd.2021.01.019.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.